Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results
Details
Publication Year 2021-08, Volume 51, Issue #8, Page 1355-1356
Journal Title
Internal Medicine Journal
Publisher
Wiley
WEHI Research Division(s)
Personalised Oncology
PubMed ID
34423539
Publisher's Version
https://doi.org/10.1111/imj.15450
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-09-17 11:04:06
Last Modified: 2021-09-17 11:06:14
An error has occurred. This application may no longer respond until reloaded. Reload 🗙